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Hyperhomocysteinemia occurs in approximately 30% of the patients with premature occlusive arterial disease
(POAD). Some of these exhibit significantly reduced fibroblast cystathionine p-synthase (CBS) activities,
suggesting that they may be heterozygous for CBS deficiency. To test this possibility, we studied cDNA
derived from four well characterized patients with POAD, exhibiting hyperhomocysteinemia and reduced CBS
activities, from four normal controls, and from four obligatory heterozygotes for CBS deficiency. Lysates of
individual colonies of E.coli, containing full-length PCR-amplification products in the expression vector,
pKK388.1, were tested for CBS activity. cDNA from at least seven of the eight possible independent POAD
alleles encoded catalytically active, stable CBS which exhibited normal response to both PLP and AdoMet.
The sequences of all 3-untranslated regions of all seven isolated POAD alleles were identical to the normal,
'wild-type' CBS sequences. The results of the expression studies were confirmed for one POAD patient by
determining the full-length cDNA sequences for both alleles; these were entirely normal over the complete
length of the cDNA. In contrast, the screening method correctly distinguished mutant from normal alleles in
all four obligatory heterozygotes studied. We conclude that CBS mRNAs from POAD individuals are free from
inactivating mutations, including all 33 previously identified in heterozygous carriers and homocystinuric
patients.
INTRODUCTION
Mild hyperhomocysteinemia (HHC) is found in approximately
one-third of cases of premature occlusive arterial disease
(POAD) (1) whereas vascular complications such as stroke
and thromboembolus are common among homocystinuric indi-
viduals (2). As a consequence, elevated plasma levels of
homocysteine are widely recognized as an independent risk
factor for such vascular disorders (1). The biochemical and
cellular participation of homocysteine in this condition is
unclear, but may involve stimulation of clotting factors V (3)
and XII (4) together with transcriptional induction of factor
III (5) and inhibition of protein C conversion (6) as well as
endothelial cell damage by peroxides (7).
Homocysteine is formed subsequently to transmethylation
from AdoMet. Normally about half of this amino acid is
resynthesized into methionine while the remainder is trans-
sulfurated to serine by cystathionine P-synthase (CBS), forming
cysteine. While blocks in either pathway can lead to elevated
plasma concentrations of homocysteine, CBS deficiency is
acknowledged to be the most frequent cause of homocystinuria
in humans (2). This enzyme is a homotetramer of 63 kDa,
encoded by a gene located at human 21q22.3 (8). Heme and
pyridoxal 5'-phosphate (9) are required for activity and the
enzyme is regulated allosterically by AdoMet (10). Homocysti-
nuria which results from CBS deficiency is inherited as an
homozygous autosomal recessive trait, in which the enzyme
activity is virtually extinguished (2). We have examined cDNAs
from a number of homocystinuric patients and identified 33
distinct pathogenic mutations to date, using a bacterial CBS
expression system which localizes the position of the mutation
(11; unpublished).
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Owing to the wide range of normal fibroblast CBS controls,
it is difficult to differentiate between low normal and hetero-
zygous-deficient enzyme activities; nonetheless, we were inter-
ested in the potential link between heterozygous CBS
deficiency and HHC/POAD. We therefore decided to employ
molecular methods to differentiate between normal and mutant
CBS alleles. These methods circumvent ambiguities originating
from the normal/heterozygous activity overlap when assayed
in fibroblast lysates.
To ascertain whether such a link existed, we examined
cDNA preparations representing seven alleles which could be
positively identified from four separate patients exhibiting
HHC/POAD. These patients were selected from 30 candidates
exhibiting POAD with accompanying HHC, exacerbated by
methionine loading (12,13). Some of these also possessed
persistent low levels of CBS in fibroblast cultures. A new
screening method was developed in which allelic products
were tested by expression of full-length cDNAs in bacteria
rather than the segmental replacement method described earlier
(14). Identification of synonymous mutations facilitated identi-
fication of the separate alleles. Lastly, we sequenced the 3'-
untranslated regions. We now report that all of the allelic
products were free from pathogenic mutations and that the
cDNA preparations expressed normal amounts of CBS in the
bacterial expression system. It appears highly unlikely that
pathogenic mutations in the coding region or the 3'-untranslated
region are responsible for the HHC observed in these patients.
RESULTS
Subjects studied
Relevant biochemical and clinical findings for the patients
studied in this report are listed in Table 1. Arteriosclerosis
was found in all four of the HHC/POAD patients. Peak plasma
homocysteine levels following a methionine load (12) were
well above normal for each of the individuals, approximating
the values observed for obligate heterozygotes. Fibroblast
cultures from three of the four exhibited CBS activities below
the normal range.
Screening strategy
We previously developed a bacterial expression method to
localize pathogenic mutations in cDNA segments from homo-
cystinuric patients (14). The aim of this study was to test for
the presence of any inactivating mutations rather than to
localize them. Therefore, we expressed the entire coding region
of each allele from each patient. The screening strategy is
summarized in Figure 1.
To date, 33 pathogenic mutations have been identified and
expressed in E.coli. Only one of these produces appreciable
CBS activity after expression, approaching 50% of the control
values. The overwhelming majority, however, completely inac-
tivate the enzyme. Figure 2 illustrates the wide separation in
CBS activity produced by normal and mutant alleles. Coupled
with Western analysis of the bacterial proteins, the method is
highly sensitive; it has never failed to localize mutations in
CBS from known homozygotes.
Screening for inactive CBS alleles among patients with
POAD/HHC
The infidelity of 7ag-catalyzed polymerase chain reaction
arises principally from the absence of proofreading in Taq
DNA polymerase. Pyrococcus DNA polymerase proofreads its
product; accordingly, its substitution for Taq DNA polymerase
significantly improved PCR fidelity. Whereas PCR of control
cDNAs with Psp polymerase produced only seven inactive
clones out of 78 (9%, Fig. 3), similar experiments with Taq
polymerase yielded five inactive clones out of 14. This 36%
error rate was too high to allow us to use the Taq enzyme
for full-length cDNA amplification, accordingly, Psp DNA
polymerase was used for all experiments.
To ascertain the suitability of this method as a screen for
heterozygosity, we first tested cDNA derived from known
heterozygotes (Fig. 3). The frequency of inactive clones from
four obligate heterozygotes (30/70; 43%) was significantly
greater than for the controls (7/78; 9%), thus the method
sensitively distinguishes between these groups. In contrast,
the frequency of inactive CBS colonies (7/63; 11 %) from the
four HHC/POAD patients was not significantly different from
the controls. These functional data suggest that it is unlikely
that the low CBS activities in this' group of POAD/HHC
patients result from mutations in the coding region of the
CBS gene, assuming that both parental alleles were equally
represented in the clones which had been analyzed.
Segregation of CBS activity with allelic polymorphisms
To eliminate the possibility that only one allelic product had
been tested in the expression studies, we examined the cloned
cDNAs for synonymous mutations in the coding regions (15).
These markers permitted us to identify both parental alleles in
Table 1. Subjects reported in this study
Subject
3014
3022
3024
3030
Obligate heterozygotes (u =
Controls (n = 30)
Sex
F/P
F/P
F/P
F
10)
Fasting HCY (uM)
8.9
5.7
5.3
9.1
4.2±2.8
0.0+0.9
Peak HCY (uM)
54.3
66.8
37.8
51.0
41.0±24.6
6.8±1.3
Site of arteriosclerosis
Internal carotid and anterior
cerebral arteries
Renal, mesenteric and iliac
arteries
Abdominal aorta and femoral
arteries
Cerebral vessels
Severity of disease
Transient ischaemic attacks
Severe reno-vascular
hypertension
Severe dysbasia
Unknown
CBS U/mg
3.5
17
3.2
5.9
0.1-1
7-30
Homocysteine (HCY) levels before (fasting) and after (peak) methionine challenge (12) are listed for each of the experimental subjects as well as normal
controls and obligate heterozygotes for CBS deficiency (mean ± 1 standard deviation). F/P: Premenopausal female patients. CBS activities for controls and
obligate heterozygotes represent the ranges found in cultured fibroblasts by this laboratory. The majority of controls range from 20-25 U/mg protein.
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individual clones exhibiting normal CBS activity. To carry out
this test, we analyzed clones derived from obligate hetero-
zygotes as well as from the POAD/HHC patients who were
informative for these polymorphisms. The results of these
experiments are summarized in Table 2.
We first tested clones from two obligate heterozygotes for
silent T/C substitutions at position 699. The triplets encoded
at that position (TAC/TAT) both encode tyrosine, therefore the
protein sequence is unaffected. Of the 12 allelic clones tested
for one patient (3056) all eight active ones exhibited 'T' alleles
(i.e. T699), whereas all four inactive clones contained ' C
alleles (C699). These results demonstrate that these polymorph-
isms segregated with active and inactive CBS alleles for this
individual. Similarly, all five active clones from 3065 exhibited
' C alleles (C699) while all five inactive clones were 'T'
alleles. These results demonstrate that the PCR-based RFLP
analytical method used (15) clearly identifies the segregated
parental alleles.
Both parental alleles were identified among active CBS
clones derived from three patients with POAD/HHC (Table
2). The T/C (699) polymorphism was found in allelic products
from patients 3022 and 3030 whereas another synonymous
CDNA
Clo I Kpn I
Cla I
J . RESTRICTION (Clal, Kpnl) C l a ' K P n 'oT4 DNA LIGASEHUMAN
CBS INSERT
ATG
EXPRESSION CONSTRUCT
pKK 388.1 CARTRIDGE
I
INDIVIDUAL E.COLI CLONES
mutation, C1080T (GCC/GCT; Ala 360), was employed to
distinguish between the allelic products from patient 3014.
The fourth patient, 3024, did not exhibit these polymorphisms,
thus it is not certain that both parental alleles were represented
in the tested clones. The presence of both these alleles in
active clones unequivocally demonstrates that both parental
alleles encode enzyme which is catalytically functional, there-
fore neither parental CBS allele encodes protein with patho-
genic mutations in these patients. These results clearly
differentiate between the obligate heterozygotes whose active
clones are all of the same haplotype and the POAD patients
whose active clones were not.
In addition, less than 15% difference was observed in CBS
activity in C and T alleles from each informative patient.
The mildest pathogenic mutation studied to date, A114V
(unpublished), decreases the activity of CBS by at least
half when the allele is expressed in E.coli. The statistically
insignificant differences between parental alleles (C and T) of
each vascular patient suggest that it is quite unlikely that these
individuals are carriers for any known mutation, even one so
mild as A114V.
DNA sequencing
Primer portion of the cloned cDNAs
The method described in this paper effectively tests the
majority of the CBS coding region, however, the sequences
of the primer portions of the cDNA escape definitive scrutiny.
Accordingly, we sequenced these regions to ascertain whether
the abnormally low fibroblast levels of enzyme activity
stemmed from cryptic mutations in the 5'- or 3'-ends of the
coding sequence. These regions were first amplified by PCR.
400 800 1200
CBS EXPRESSION PLASMID DNA ANALYSES
CBS ASSAY RESTRICTION ANALYSIS
WESTERN BLOT SYNONYMOUS MUTATION SCREEN
DNA SEQUENCING
Figure 1. Expression system in E.coli. Patient cDNA was amplified by PCR
using the primers (boxes) described in the text which contained artificial Clal
and Kpnl sites. The PCR products were restricted with Clal and Kpnl, purified
and ligated into pKK 388.1 cartridge. Resulting constructs contained cDNA
sequence which was derived from tested individuals except of the small
portion incorporated from the primers (shadowed portions). The constructs
were used for E.coli transformation and individual clones were isolated. CBS
was expressed after induction with IPTG, plasmid DNA of the clones was
used for restriction analysis, sequencing or synonymous mutation screening.
CBS ACTIVITY (U/ml)
Figure 2. Distribution of CBS activity in separated normal and mutant alleles.
A total of 211 colonies from normal, obligate heterozygotes and POAD/HHC
patients were assayed for CBS. Enzyme activity (U/ml lysate) is depicted on
the abscissa of the histogram; the number of colonies found in each 100 U/
ml division is indicated on the ordinate. Individual colonies were scored as
inactive within the 0-100 U/ml division (black). Active colonies exhibited
CBS values greater than 400 U/ml (slanted stripes). Four colonies exhibited
CBS activities between 100 and 400 U/ml (vertical stripes) and were not
scored. The mean activity for the 44 inactive clones, originating predominantly
from the obligate heterozygotes, was IO.8±3.3 (standard error of the mean);
for the 163 normal clones, 807 ±13.
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In the 5'-portion, between six and eight clones derived from
each patient were chosen for sequencing to limit the probability
that only one parental allele was tested. The 5'-ends were
sequenced from nts —1 to 40, covering the entire region
occupied by the sense primer. All of the clones in all four
patients possessed normal cDNA sequence in this region.
Sequencing of the 3' untranslated region
We next searched for mutations in the 3'-sequence of the
cDNA using a similar strategy. To ensure that both parental
alleles were represented in the clones, we tested the individual
colonies for a frequent Msp I polymorphism (T2199C) in the
3'-untranslated region. Three of the patients were polymorphic,
thus only two clones (each representing one allele) were
chosen for DNA sequencing. The sequence of the plasmids
harboring these cDNAs was indistinguishable from normal in
the region homologous to the antisense primer as well as in
the 3'-untranslated region. Four plasmids originating from
patient 3024, who did not exhibit the Mspl polymorphism,
were also sequenced through the antisense primer region
further into the 3'-untranslated region and were also fully
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Figure 3. Distribution of active and inactive E.coli clones from controls,
POAD patients, and CBS heterozygotes. Individual E.coli colonies were
assayed for CBS activity and scored according to the criteria described in the
legend of Figure 2. The average number of colonies examined for each patient
was 18 while the range was 13-25. Each cell line is listed on the left. The
percentage of positive clones is indicated by the length of the striped bar;
negative clones by the black bar. The right side of the figure indicates the
fractions and percentages of negative clones for each group. CBS cDNAs
containing pathogenic mutations in 32/33 alleles from homocystinurics produce
inactive clones.
congruent with the normal allele. These results demonstrate
the absence of cryptic mutations in both the 5'- and 3'-coding
regions and 3' untranslated region of CBS cDNA.
DNA sequencing of full length cDNA in patient 3014
To search for other DNA mutations which might be undetect-
able in our screening system, we sequenced the entire coding
region of CBS cDNA from both alleles of one patient (3014).
The Ala36O synonymous mutation in the coding region was
used to identify cDNA clones originating from separate alleles.
The sequence of both alleles were completely normal over
their entire coding regions.
Activation of patient CBS by S-adenosylmethionine
Incubation of 'wild-type' CBS with AdoMet stimulates the
enzyme's activity by increasing its affinity for homocysteine
(10,14). Subtle mutations in the AdoMet binding region,
displacing the effector from its binding site, might reduce the
enzyme activity to the levels observed in the fibroblasts
from the four patients studied. These mutations would be
accompanied by a lack of response of the enzyme to AdoMet.
We measured CBS activity in fibroblast lysates, and in bacterial
extracts, incubated with added AdoMet varying from 0-500
LtM and calculated the activation constant, Kacl, for AdoMet
to determine whether such mutations might exist. Figure 4
depicts the results of the fibroblast study. Although the basal
activities differed considerably, CBS in each patient cell extract
responded to AdoMet similarly. Both the 15 LiM AdoMet
activation constant and the 2.5-fold increase in enzyme activity
were identical for the patients and controls. These results
indicate that the AdoMet binding domains for CBS in all
patient lines are intact and that the endogenous AdoMet
concentration in the cell cultures are similar in each cell line.
CBS, expressed in E.coli, behaved similarly when incubated
with varying concentrations of AdoMet (data not shown).
These results demonstrate unequivocally that both alleles of
each patient encode CBS with identical behavior towards
AdoMet; accordingly, the wide variation in the CBS activities of
these patients cannot be ascribed to defective AdoMet binding.
Analysis of cloned CBS by Western blotting
Since all of the CBS clones were free from pathogenic
mutations, we suspected that the low intracellular CBS activit-
ies might be attributed to decreased amounts of normal enzyme
subunits. The volumes of fibroblast extracts were adjusted so
that each sample contained equal amounts of enzyme activity.
Table 2. Distribution of CBS activity between parental alleles
Cell line C-Alleles
No. clones Activity
T-Alleles
No. clones Activity
Obligate
heterozygotes
POAD/HHC
patients
3056
3065
3014
3022
3030
010s
679±5la
469±57b
1020±53b
793±122b
829±78a
0±0a
540±80b
95O±87b
916±58b
Full-length CBS cDNAs were prepared from fibroblast mRNAs for each cell line listed in the table, cloned into pKK388.1, resolved and expressed in transformed
E.coli as described in Materials and Methods. Separate parental alleles (C-alleles or T-alleles) were identified by the presence of common synonymous mutations:
CI080T (Ala360), 3014; C699T(Tyr233), all others. No synonymous mutations were found for 3024. The activity columns refer to mean CBS activity ± I
standard deviation of the mean for the number of clones indicated in the columns to the left. *C and T alleles which differ significantly by Student's f-test
(p<0.001). bC and T alleles not significantly different (p>0.2).
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Immunoprecipitates of these samples were analyzed by Western
blotting to estimate the actual amount of enzyme in each.
Comparable band intensities resulted from identical amounts
of enzyme activity even though 20-fold more total cellular
protein was required for the defective cell lines (Fig. 5, upper
panel). We conclude that the specific activity of the pure
enzyme molecules is constant in each fibroblast line and that
the low CBS activity found in these lines results from decreased
amounts of enzyme molecules rather than impaired catalytic
activity. These conclusions were further supported by the
following bacterial studies.
All seven separated alleles were examined by Western
blotting of the E.coli lysates. Whereas the quantity of crude
fibroblast protein required to produce a constant (2 U) amount
of CBS was quite variable, bacterial lysates were far more
consistent, even when the colonies expressed separate CBS
alleles (Fig. 5, lower panel). These results demonstrate that
the specific activity of the cloned CBS subunits does not vary
in clones derived from separated parental alleles. Additionally,
they reveal that the enzyme proteins encoded by each allele
are equally stable in E.coli, as would be expected if each allele
encoded an identical product.
DISCUSSION
The purpose of this research was to ascertain whether the
hyperhomocysteinemia observed in the four patients studied
originated from mutations in the CBS coding region. At least
seven of the eight possible alleles were examined and did
not contain mutations. We therefore conclude that the HHC
observed in these four individuals does not stem from defective
CBS protein. CBS binds three cofactors in addition to its two
substrates: PLP (16), AdoMet (10,14), and heme (9). All of
these affect CBS activity. PLP is an active participant in the
reaction (16), AdoMet stimulates the enzyme allosterically
(10,14), while heme is required for both PLP binding and
enzyme activity (9). Fibroblast cultures from three of the four
patients exhibited low enzyme activities upon repeated assay.
It is unlikely that these resulted from reduced PLP affinity
since the enzyme responded normally when assayed in both
the presence and absence of this cofactor (data not shown);
additionally, altered PLP affinity is associated with mutations
in the coding region (17) and none were found. AdoMet
sensitivity, likewise, was unaffected for all of the preparations
(Fig. 4). CBS specific activity depends upon its saturation with
heme (9). This porphyrin binds tightly to CBS and is evidently
inserted either concurrently with or shortly after synthesis.
Addition of heme to enzyme incubations is without effect on
either crude or pure preparations of the enzyme (9) so it is
not possible to test directly the affinity of CBS for heme.
Western analyses of the proteins from fibroblasts, however,
demonstrated that the amount of CBS protein closely correlated
to the levels of CBS activity (Fig. 5) so it is likely that the
heme saturation is equal for the normal and HHC/POAD
samples. These results imply that the reduced amounts of
CBS in the fibroblast samples resulted from altered enzyme
expression rather than a mutation in its structure.
The clear separation of activity between normal and mutant
alleles in this screening method (Fig. 2) greatly simplifies
identification of bacterial colonies harboring plasmids con-
taining mutant CBS cDNAs. The substitution of Psp DNA
polymerase, which proofreads its products, for Taq, which
does not, significantly improved the sensitivity of the method.
Fidelity of the screening method depends directly upon fidelity
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Figure 4. Activation of CBS in fibroblast extracts by AdoMet. Fibroblast
extracts were assayed for CBS activity in the presence of AdoMet (exogenous
concentrations were 0, 10, 50 and 500 (iM). Numbers on the bottom signify
the cell line examined, 1996 is a control cell line. The individually shadowed
columns represent the fraction of maximum CBS activity (maximum was at
500 U.M AdoMet concentration). The maximum CBS activities obtained for
each cell line were 8.6 U/mg total cellular protein for 3014; 24 for 3022; 5.4
for 3024; 19.4 for 3030; and 72.8 for 1996.
Figure 5. Western analyses. The upper panel shows 2 units of CBS activity
immunoisolated from fibroblast extracts and subjected to Western analysis.
Numbers at the bottom of this panel represent the amounts of total cellular
protein used to immunoisolate the identical CBS activities. The lower panel
compares intensity of bands originating from each cloned parental allele
(signified as letters a and b next to the cell line number) when 2 units of CBS
were immunoisolated, run on SDS/PAGE and blotted. Total bacterial protein
subjected to the analysis is indicated at the bottom.
628 Human Molecular Genetics, 1995, Vol. 4, No. 4
of the polymerase. This was tested by PCR of normal CBS
cDNA sequences. Using Taq polymerase, less than 2/3 of the
PCR products encoded active CBS when a normal plasmid
template was amplified. More than 90% of the Psp polymerase
control products were active.
All of the known mutations associated with homocystinuria
impact considerably on CBS activity expressed in transformed
bacteria (11; unpublished). There was no significant difference
in the frequency of inactive clones between the HHC/POAD
patient and the normal control groups; although considerable
variation was observed between individuals in the obligate
heterozygote group. In addition, screening for synonymous
mutations allowed us to show that individual parental CBS
alleles were tested for pathogenic mutations in three of the
patients. All of the coding regions of these sequences were
free from pathogenic mutations. This was not the case for the
obligate heterozygotes which were unequivocally differentiated
from the controls. We subsequently separated the allelic
products from the obligate heterozygotes and identified the
mutations in the abnormal strand (14,21; unpublished). This
method permits unequivocal identification of heterozygous
carriers for homocystinuria for the first time.
Since at least three of these patients are homozygous for
normal CBS, their hyperhomocysteinemias evidently stem
from other factors. Homocysteine, once formed, can either
serve as a substrate for transsulfuration or be resynthesized
into methionine (2). Although the most frequent cause of
homocystinuria is CBS deficiency (2), the condition may
arise from inadequate methionine resynthesis as well (18,19).
Defects in cobalamin metabolism (19) or methylenetetra-
hydrofolate reductase insufficiency (18) could precipitate
hyperhomocysteinemia in these subjects. Other defects could
include vitamin malnutrition with or without attenuated heme
biosynthesis, or concurrent low expression of key enzymes
such as methylenetetrahydrofolate reductase and CBS. The
rate of methionine resynthesis is currently under investigation
to evaluate its contribution to these patients' condition.
Lastly, it is important to note that there is a strong overlap
of the normal and heterozygote CBS activity ranges in cultured
fibroblasts (20). Three of the patients studied were below the
normal range while the fourth patient was well within it. Our
initial intent was to evaluate whether they were heterozygous
for CBS deficiency. With this publication, we demonstrate that
they were all homozygous for normal CBS. In many cases,
fibroblast cultures have been in passage for some time. In
others, the phase of the culture may not be reliably determined.
Each of these conditions can affect the level of enzyme assays,
including those for CBS. Considerable variability in CBS
activity may occur within cultures of apparently healthy
fibroblasts as well. These considerations together with our
results indicate that fibroblast CBS activities alone cannot be
used to assess the CBS zygosity of a patient, even when
accompanied by hyperhomocysteinemia; accordingly, the dia-
gnosis of individuals suspected of being carriers of homocystin-
uria must be based on analysis of their nucleic acid sequences.
MATERIALS AND METHODS
Patients and cell lines
Cell lines 3014, 3022, 3024, and 3030 from POAD/HHC patients used in
these studies originated from two clinical and biochemical studies described
elsewhere (12,13). Cell lines 2047, 2103 and 3077 were from controls and
367, 3009, 3056 and 3065 were from mothers of homocystinuric patients.
The mutations in these obligate heterozygotes were 1278T, E239K, G307S,
and R336C, respectively (14,21; unpublished). Fibroblasts were cultured in
MEM with 10% fetal calf serum, nonessential amino acids, glutamine, 100
U/ml of kanamycin and 100 Hg/ml of streptomycin.
PCR amplification of cDNA
DNA was amplified using Pyrococcus sp. GB-D DNA polymerase (Psp, Deep
Vent Polymerase, New England Biolabs, Beverly, MA) or with Taq polymerase
as noted in the results section. Complementary DNA was synthesized from
mRNA as described previously (14). Diluted target strands were completely
denatured prior to PCR by heating to 95°C for 3 min and rapidly chilling in
an ice/water bath.
Each 100 nl reaction mixture for PCR with the Deep Vent enzyme contained
1 nl of cDNA, 1 X Deep Vent buffer (NEB), 300 \iM of each dNTPs, 80 pmol
of both sense and antisense primers (described above), 4% dimethylsulfoxide
and 8 mM MgSO4. Conditions for 7a^-mediated PCR were: 2.5 Hi cDNA,
10 mM TRIS.HC1 (pH 8.4), 50 mM KCI, 0.01% gelatin, 200 HM of each
dNTPs, 1.5 mM MgCl2 and 80 pmol of both the sense and antisense primers
contained in a total of 100 |il. Primer sequences for both sets of PCRs were:
Sense primer 5'-TACGATCGATAAGGAGGTTTAAACCATGGjGJTCTG-
AGACCCCCCAG-3'. The bold portion of the sense primer hybridized to
the 5' coding region of CBS cDNA. The underlined codon following the
initiator ATG was changed from proline to glycine to complete a Nco I site;
this change coincidentally increased the activity of CBS. The nonhybridizing
portion of the primer contained a prokaryotic ribosome binding site and a Cla
I site; Antisense primer 5-TACGGGTACCAGCGCTCCGGACTTCACTT-
CTGG-3'. The bold portion was complementary to the 3' region of the cDNA
whereas the remainder contained an artificial Kpn I site.
PCR was conducted in a Techne PHC-1 thermocycler with block temperature
control when the Deep Vent enzyme was used. The reaction mixture was
preheated to 80°C/5 min and I U of Psp polymerase was added to each tube.
The temperature was cycled 30 times (96°C/1 min; 6I°C/I min; 72°C/2.3
min) to amplify target DNA. The Techne thermocycler produced uniform
results with this enzyme whereas the reactions did not proceed well with the
Hybaid TR1, used for 7a<7-amplified PCR.
The Hybaid TR1 thermal reactor with tube temperature monitoring was
employed for Taq DNA polymerase PCR. Enzyme was added after preheating
to 80°C/5 min, then the mixture was cycled as follows: 1 cycle (94°C/3 min,
50°C/l min, 72°C/3 min), 4 cycles (94°C/1.5 min, 50°C/l min, 72°C/3 min),
24 cycles (94°C/1.5 min, 55°C/1 min, 72°C/2 min) and final cycle (94°C/1.5
min, 55°C/1 min, 72°C/4 min).
PCR products were purified, restricted with Cla I and Kpn I, gel purified,
andligated in gel into similarly prepared pKK388.1 (14). Individual, ampicillin-
resistant colonies of transformed DH5aFI'Q E.coli were subsequently used
to express CBS or prepare plasmid DNA.
CBS expression in E.coli
Enzyme activity was measured in 20 (ll lysates of transformed cells grown
from individual colonies after incubation with IPTG (isopropylthio-p"-D-
galactoside, GIBCO BRL, Gaithersburg, MD) as fully described elsewhere
(14). One unit of CBS activity was defined as 1 nmol of cystathionine
produced in 1 h at 37°C. This radiometric assay can reliably detect enzyme
activity as low as 0.03 U (100 CPM above background).
Analysis of synonymous mutations
Three synonymous mutations in the coding region of CBS cDNA and one
polymorphism in the 3' untranslated region (G573A; C699T; TI080C; T2199C)
were analyzed by a PCR-based RFLP method described elsewhere (15).
cDNA sequencing
A 5'- portion of CBS cDNA in all four PAD/HHC patients was amplified
by PCR between nucleotides —2 and 272 using the sense primer 5'-
CGTAGAATTCCAGCACCATCTGTCCGGTCCCA-3', together with the
antisense primer 5'-TACGATCGATTCAGG-CCGAACTTCTTCCCAAT-3'.
Reaction conditions were identical to those described for Psp PCR except
that 4 mM MgSO4 was used and 30 cycles of amplification (96°C, I min;
55°C, 1 min; 75°C, 30 s) were carried out. PCR products were restricted with
Cla I/Eco RI, subcloned into a pBlueScript KS(+) cartridge and the resulting
plasmid preparations used for sequencing. A 3'-portion of CBS cDNA of all
four patients between nucleotides 1462 and 2316 was similarly amplified with
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Psp polymerase using the sense primer P5, 5'-CGTAGAATTCAAAGTCAT-
CTACAAGCAGTTC-3', and the antisense primer P6, 5'-TACGATCG-
ATGTGTGATTCCATTTATATG-AAATGTCC-3'. Thermocycling conditions
were: 30 cycles of 96°C, 1 min; 64°C, 1 min and 72°C, 54 s. The entire CBS
cDNA coding regions between nucleotides 22 and 1646 from both alleles of
patient 3014 were cloned and sequenced.
Other methods
Magic MiniPrep kits (Promega, Madison, WI) were used to prepare plasmid
DNA. Restriction endonucleases and T4 ligase were purchased from NEB
(Beverly, MA). DNA was sequenced by the dideoxy method (23) using the
CircumVent kit (NEB). Competent cells (DH5aF'IQ) were obtained from
Gibco BRL.
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